The US Food and Drug Administration (FDA) has issued a warning letter to Purolea Cosmetics Lab for several violations of Good ...
The US Food and Drug Administration (FDA) has issued warning letters to several drug and device manufacturers for failing to meet its current good manufacturing practices (CGMP). Among the violations, ...
The future of pharmaceutical facilities is linked to digitalization, which serves as the foundation for leveraging data ...
The main market opportunities include enhancing pharmaceutical manufacturing quality through advanced cGMP training, reducing violations, and improving operational efficiency by adhering to FDA ...
A Critical Next Step in Advancing Phio’s PH-762 Program to Treat Cutaneous Carcinomas Phio Pharmaceuticals Corp.
SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's ...
OKLAHOMA CITY, April 13, 2023 /PRNewswire/ -- Wheeler Bio, Inc., a boutique contract development and manufacturing organization (CDMO) specializing in process development and small batch CGMP ...
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform Esco Aster, a vertically integrated ...
KING OF PRUSSIA, PA, UNITED STATES, April 1, 2026 /EINPresswire.com/ — Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results